within Pharmacolibrary.Drugs.H_SystemicHormonalPreparationsExclSexHormonesAndInsulins.H01C_HypothalamicHormones.H01CB02_Octreotide;

model Octreotide_1
  extends Pharmacolibrary.Drugs.ATC.H.H01CB02_1;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>H01CB02_1</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Octreotide is a synthetic octapeptide and somatostatin analogue that inhibits the release of several hormones such as growth hormone and insulin. It is used clinically for the management of acromegaly, treatment of severe diarrhea and flushing associated with carcinoid tumors, vasoactive intestinal peptide tumors (VIPomas), and other neuroendocrine tumors. Octreotide is currently approved and in use for these indications.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers after intravenous bolus injection.</p><h4>References</h4><ol><li><p>Ottesen, LH, et al., &amp; Bendtsen, F (1997). The pharmacokinetics of octreotide in cirrhosis and in healthy man. <i>Journal of hepatology</i> 26(5) 1018–1025. DOI:<a href=&quot;https://doi.org/10.1016/s0168-8278(97)80110-9&quot;>10.1016/s0168-8278(97)80110-9</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/9186832/&quot;>https://pubmed.ncbi.nlm.nih.gov/9186832</a></p></li><li><p>Chanson, P, et al., &amp; Harris, AG (1993). Clinical pharmacokinetics of octreotide. Therapeutic applications in patients with pituitary tumours. <i>Clinical pharmacokinetics</i> 25(5) 375–391. DOI:<a href=&quot;https://doi.org/10.2165/00003088-199325050-00004&quot;>10.2165/00003088-199325050-00004</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/8287633/&quot;>https://pubmed.ncbi.nlm.nih.gov/8287633</a></p></li><li><p>Biermasz, NR, et al., &amp; Roelfsema, F (2005). Intravenous octreotide test predicts the long term outcome of treatment with octreotide-long-acting repeatable in active acromegaly. <i>Growth hormone &amp; IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society</i> 15(3) 200–206. DOI:<a href=&quot;https://doi.org/10.1016/j.ghir.2005.02.007&quot;>10.1016/j.ghir.2005.02.007</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/15935982/&quot;>https://pubmed.ncbi.nlm.nih.gov/15935982</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Octreotide_1;
